Morgan Anyla1, Jérémie H Lefevre2,3, Ben Creavin4, Chrystelle Colas5,6, Magali Svrcek4,6, Olivier Lascols7, Clotilde Debove1, Najim Chafai1, Emmanuel Tiret1, Yann Parc1,8. 1. Department of Digestive Surgery, St Antoine Hospital (AP-HP), Sorbonne Université, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. 2. Department of Digestive Surgery, St Antoine Hospital (AP-HP), Sorbonne Université, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. jeremie.lefevre@aphp.fr. 3. Equipe "Instabilité des Microsatellites et Cancers", Equipe labellisée par la Ligue Nationale contre le Cancer, INSERM, UMRS 938 - Centre de Recherche Saint-Antoine, 75012, Paris, France. jeremie.lefevre@aphp.fr. 4. Centre for Colorectal Disease, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland. 5. Department of Oncogenetics and Angiogenetics, Pitie-Salpetriere Hospital, Sorbonne Université, Paris, France. 6. Department of Pathology, St Antoine Hospital (AP-HP), Sorbonne Université, Paris, France. 7. Department of Molecular Biology, St Antoine Hospital (AP-HP), Sorbonne Université, Paris, France. 8. Equipe "Instabilité des Microsatellites et Cancers", Equipe labellisée par la Ligue Nationale contre le Cancer, INSERM, UMRS 938 - Centre de Recherche Saint-Antoine, 75012, Paris, France.
Abstract
PURPOSE: Regular follow-up for patients with Lynch syndrome (LS) is vital due to the increased risk of colorectal (50-80%), endometrial (40-60%), and other cancers. However, there is an ongoing debate concerning the best interval between colonoscopies. Currently, no specific endoscopic follow-up has been decided for LS patients who already have an index colorectal cancer (CRC). The aim of this study was to evaluate the risk of metachronous cancers (MC) after primary CRC in a LS population and to determinate if endoscopic surveillance should be more intensive. METHODS: A prospective cohort of patients with a confirmed diagnosis of hereditary CRC since 2009 was included. Patients with LS and a primary CRC were the cohort of choice. RESULTS: One hundred twenty-one patients were included with a median age of 44 years(16-70). At least one MC occurred in 39 patients (32.2%), with a median interval of 67 months (6-300) from index cancer. Fifteen (38.5%) developed two or more MCs during follow-up, with a median number of two (2-6) tumors occurring. Metachronous CRC were diagnosed after a median interval of 24 (6-57) months since last colonoscopy and were more commonly seen in MSH2 mutation carriers (58 vs. 35%, p = 0.001). After a median follow-up of 52.9 (3-72) months, no cancer-related deaths were recorded. CONCLUSION: Patients with LS have an increased risk of MC, especially CRCs. With a median time period of 24 months between colonoscopy and metachronous CRC, the interval between surveillance colonoscopies following primary CRC should not exceed 18 months, especially in patients with MSH2 mutation.
PURPOSE: Regular follow-up for patients with Lynch syndrome (LS) is vital due to the increased risk of colorectal (50-80%), endometrial (40-60%), and other cancers. However, there is an ongoing debate concerning the best interval between colonoscopies. Currently, no specific endoscopic follow-up has been decided for LS patients who already have an index colorectal cancer (CRC). The aim of this study was to evaluate the risk of metachronous cancers (MC) after primary CRC in a LS population and to determinate if endoscopic surveillance should be more intensive. METHODS: A prospective cohort of patients with a confirmed diagnosis of hereditary CRC since 2009 was included. Patients with LS and a primary CRC were the cohort of choice. RESULTS: One hundred twenty-one patients were included with a median age of 44 years(16-70). At least one MC occurred in 39 patients (32.2%), with a median interval of 67 months (6-300) from index cancer. Fifteen (38.5%) developed two or more MCs during follow-up, with a median number of two (2-6) tumors occurring. Metachronous CRC were diagnosed after a median interval of 24 (6-57) months since last colonoscopy and were more commonly seen in MSH2 mutation carriers (58 vs. 35%, p = 0.001). After a median follow-up of 52.9 (3-72) months, no cancer-related deaths were recorded. CONCLUSION:Patients with LS have an increased risk of MC, especially CRCs. With a median time period of 24 months between colonoscopy and metachronous CRC, the interval between surveillance colonoscopies following primary CRC should not exceed 18 months, especially in patients with MSH2 mutation.
Authors: Matthew F Kalady; Ellen McGannon; Jon D Vogel; Elena Manilich; Victor W Fazio; James M Church Journal: Ann Surg Date: 2010-09 Impact factor: 12.969
Authors: Hans F A Vasen; Mohamed Abdirahman; Richard Brohet; Alexandra M J Langers; Jan H Kleibeuker; Mariette van Kouwen; Jan Jacob Koornstra; Henk Boot; Annemieke Cats; Evelien Dekker; Silvia Sanduleanu; Jan-Werner Poley; James C H Hardwick; Wouter H de Vos Tot Nederveen Cappel; Andrea E van der Meulen-de Jong; T Gie Tan; Maarten A J M Jacobs; Faig Lall A Mohamed; Sijbrand Y de Boer; Paul C van de Meeberg; Marie-Louise Verhulst; Jan M Salemans; Nico van Bentem; B Dik Westerveld; Juda Vecht; Fokko M Nagengast Journal: Gastroenterology Date: 2010-03-02 Impact factor: 22.682
Authors: Susan Parry; Aung Ko Win; Bryan Parry; Finlay A Macrae; Lyle C Gurrin; James M Church; John A Baron; Graham G Giles; Barbara A Leggett; Ingrid Winship; Lara Lipton; Graeme P Young; Joanne P Young; Caroline J Lodge; Melissa C Southey; Polly A Newcomb; Loïc Le Marchand; Robert W Haile; Noralane M Lindor; Steven Gallinger; John L Hopper; Mark A Jenkins Journal: Gut Date: 2010-12-30 Impact factor: 23.059
Authors: Kathleen M Schmeler; Henry T Lynch; Lee-may Chen; Mark F Munsell; Pamela T Soliman; Mary Beth Clark; Molly S Daniels; Kristin G White; Stephanie G Boyd-Rogers; Peggy G Conrad; Kathleen Y Yang; Mary M Rubin; Charlotte C Sun; Brian M Slomovitz; David M Gershenson; Karen H Lu Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: Elena M Stoffel; D Kim Turgeon; David H Stockwell; Lili Zhao; Daniel P Normolle; Missy K Tuck; Robert S Bresalier; Norman E Marcon; John A Baron; Mack T Ruffin; Dean E Brenner; Sapna Syngal Journal: Cancer Prev Res (Phila) Date: 2008-11
Authors: R Hüneburg; F Lammert; C Rabe; N Rahner; P Kahl; R Büttner; P Propping; T Sauerbruch; C Lamberti Journal: Endoscopy Date: 2009-04-01 Impact factor: 10.093
Authors: Jordan J Karlitz; Meredith R Sherrill; Daniel V DiGiacomo; Mei-Chin Hsieh; Beth Schmidt; Xiao-Cheng Wu; Vivien W Chen Journal: Clin Transl Gastroenterol Date: 2016-04-14 Impact factor: 4.488
Authors: Felipe F Quezada-Diaz; Irbaz Hameed; Alexa von Mueffling; Erin E Salo-Mullen; Alice Catalano; J Joshua Smith; Martin R Weiser; Julio Garcia-Aguilar; Zsofia K Stadler; Jose G Guillem Journal: J Am Coll Surg Date: 2020-01-30 Impact factor: 6.532
Authors: Simon Wieser; Maria C Katapodi; Islam Salikhanov; Karl Heinimann; Pierre Chappuis; Nicole Buerki; Rossella Graffeo; Viola Heinzelmann; Manuela Rabaglio; Monica Taborelli Journal: J Med Genet Date: 2021-11-15 Impact factor: 5.941